Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.7 USD | +2.66% | +5.06% | -35.71% |
05-20 | Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index | CI |
05-17 | First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.21M 487M |
---|---|---|---|---|---|
Net income 2024 * | -10M -785M | Net income 2025 * | -32M -2.51B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.39
x | P/E ratio 2025 * |
-1.78
x | Employees | 9 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.34% |
1 day | +2.66% | ||
1 week | +5.06% | ||
1 month | -4.93% | ||
3 months | -70.78% | ||
6 months | -52.63% | ||
Current year | -35.71% |
Managers | Title | Age | Since |
---|---|---|---|
James Sapirstein
CEO | Chief Executive Officer | 63 | 07/10/19 |
Sarah Romano
DFI | Director of Finance/CFO | 44 | 28/02/22 |
Amy Chandler
CMP | Compliance Officer | 56 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 02/03/17 | |
Ed Borkowski
BRD | Director/Board Member | 64 | 30/04/15 |
Alastair Riddell
BRD | Director/Board Member | 74 | 31/08/15 |
Date | Price | Change | Volume |
---|---|---|---|
31/05/24 | 2.7 | +2.66% | 14,364 |
30/05/24 | 2.63 | +2.33% | 30,158 |
29/05/24 | 2.57 | -.--% | 35,810 |
28/05/24 | 2.57 | -.--% | 29,255 |
24/05/24 | 2.57 | -8.87% | 11,532 |
Delayed Quote Nasdaq, May 31, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.71% | 6.21M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- ENTO Stock